UCB’s Board of Directors appoints Jonathan Peacock as new Chair
UCB SA/NV announces the following changes to its Board of Directors.
During its meeting on March 8, 2023 UCB’s Board of Directors elected Jonathan Peacock, currently Independent Director and Chair of the Audit Committee at UCB, as Chair of UCB's Board of Directors with effect as of March 9, 2023. Fiona du Monceau, currently ad interim Chair of the Board, will revert to her role as Vice Chair of the Board. Ad interim, Jonathan Peacock will also keep his role as Chair of the Audit Committee at UCB.
Jean-Christophe Tellier, UCB's CEO said: “Jonathan Peacock is a highly respected and appreciated member of the Board and Chair of its Audit Committee since 2021, bringing a wealth of expertise and strategic leadership. We are delighted to see Jonathan, who always puts the patient’s perspective first, take on the role as Chair of the Board of UCB. Special thank you to Fiona du Monceau who acted as ad interim Chair during year-end closing on top of her duties.”
“I am thrilled to take on this unique opportunity and continue to work with such inspiring and talented people across the Board and UCB. The past years as Chair of the Audit Committee have provided me in-depth knowledge of the company, its culture and strategy. I look forward to now also bringing my expertise and leadership to the role of Chairman of UCB and accompanying UCB on the exciting journey it has ahead, striving to help people to live the best life they can.” said Jonathan Peacock.
Jonathan Peacock joined the Board of UCB in 2021 as an Independent Director and Chair of the Audit Committee. He currently serves as Chair of the Board of Avantor Inc and is a member of the Nominating and Governance Committee. He also serves on the Board of 2 private companies, Bluesphere Bio, as Chairman, and Real Chemistry.
From 2014 to May 2021, Mr. Peacock served as the Chairman of Bellerophon Therapeutics, Inc. a clinical stage biotherapeutics company, and was its CEO from 2014 to 2016. He also served as Chairman of Arix Bioscience plc from 2016-2020 and as Chair of the Audit and Finance Committee of Kite Pharma from 2014-17 and Member of the Board of Genmab A/S until November 2021. Mr. Peacock held Global CFO roles at Amgen and Novartis Pharma and leadership roles in Strategy and Corporate Finance as a partner at McKinsey and Price Waterhouse. He has experience in emerging Biotechnology, big Pharma and Corporate Finance in Europe, the US and Asia. He also has extensive IPO and fund-raising experience on NASDAQ, NYSE and LSE.